AI Insight
This study identifies the methionine cycle, particularly the enzyme S-adenosylhomocysteine hydrolase (SAHH), as crucial for maintaining mesenchymal traits in pancreatic cancer cells that drive metastasis. Researchers found that metastatic tumor cells rely more heavily on the methionine cycle than primary tumors, and that inhibiting SAHH in mesenchymal cancer cells disrupts antioxidant defenses and calcium balance, reversing mesenchymal characteristics and reducing tumor growth and spread. In patient data, high SAHH expression in mesenchymal pancreatic cancer correlates with poor survival outcomes.
Why it matters
This research identifies a potential therapeutic vulnerability in aggressive mesenchymal pancreatic cancer cells, which are currently difficult to target. SAHH inhibition could offer a new treatment strategy to prevent metastasis and improve outcomes for pancreatic cancer patients with the poorest prognoses.
Understand the Science
⚠️ Preprint – Noch nicht peer-reviewed
Dieser Artikel wurde noch nicht von unabhängigen Experten begutachtet. Die Ergebnisse sind vorläufig und sollten mit Vorsicht interpretiert werden.
Mesenchymal traits are associated with poor prognosis in Pancreatic Ductal Adenocarcinoma (PDA), but direct targeting of mesenchymal tumor cells remains a challenge. Metabolic profiling of tumor cells isolated from murine PDA and liver metastases (LM) revealed that LM rely more on the methionine cycle than does primary PDA. This metabolic shift was specifically associated with increased activation of the methionine cycle in mesenchymal tumor cells compared to differentiated tumor cells. We show that the targeting of the key enzyme of the methionine cycle S-adenosylhomocysteine hydrolase (SAHH) in mesenchymal cells lowers the levels of homocysteine (Hcy) and glutathione, resulting in reduced antioxidant capacity, deregulated intracellular calcium homeostasis, and ultimately loss of mesenchymal markers. Together, these events decrease cell proliferation and invasion, blunting the tumorigenic and metastatic potential of SAHH-deficient cells, eventually impeding tumor growth and progression of the metastatic disease. Clinically, the high expression of SAHH in patients with mesenchymal PDA is correlated with poor survival, positioning SAHH as a potential therapeutic target to impede the pro-metastatic, mesenchymal phenotype of PDA.
Source: The methionine cycle sustains the mesenchymal phenotype of tumor cells and drives PDA progression